NCT00093964 2019-04-16
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
EMD Serono
Phase 2 Completed
Clinical Trials
7 trialsNCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00112866 2017-06-14
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01044225 2012-03-22
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Universitair Ziekenhuis Brussel
Phase 2 Terminated
NCT01124240 2011-07-26
ExCentric
Northern Sydney and Central Coast Area Health Service
Phase 2 Unknown